老年患者出院后苯二氮䓬类药物停药模式及相关因素
该回顾性队列研究基于Optum CDM数据库(2004–2025年),纳入33,449例住院后30天内新启用苯二氮䓬类药物的≥65岁患者,排除焦虑、精神疾病、酒精滥用、癫痫及临终关怀者。结果显示30、60、90天停药率分别为53.3%、86.7%、92.6%,30天停药率从2004年31.7%升至2024年71.1%,失眠、中重度衰弱及新用抗抑郁药/非典型抗精神病药与较低停药率相关。
要点
- 住院后新启用BZD的老年患者30天停药率53.3%,90天达92.6%。
- 30天停药率从2004年31.7%升至2024年71.1%,年均增长4%。
- 失眠、中重度衰弱及新用抗抑郁药/非典型抗精神病药者停药可能性更低。
核心结论
- 无精神疾病史的老年患者住院后BZD停药率随时间上升,但失眠和中重度衰弱者停药仍具挑战。
研究设计与样本
- 回顾性队列研究,使用Optum CDM数据库(2004年1月至2025年2月),纳入33,449例≥65岁住院后30天内新启用BZD的患者。
主要发现
- IPW加权30、60、90天BZD停药率分别为53.3%(95%CI 52.7%-53.8%)、86.7%(86.3%-87.1%)、92.6%(92.3%-93.0%)。
- 30天停药率从2004年31.7%(29.5%-33.9%)升至2024年71.1%(68.7%-73.5%),研究期间年增长4%。
- 失眠(HR 0.66,95%CI 0.63-0.69)、中重度衰弱(HR 0.82,0.75-0.90)、新用抗抑郁药(HR 0.80,0.76-0.85)和非典型抗精神病药(HR 0.90,0.82-0.99)与较低停药率相关。
关键数值与推荐
- BZD停药定义为处方结束后超过15天的间隙。
- 纳入标准:年龄≥65岁,住院后30天内新启用BZD处方。
- 排除标准:焦虑、精神疾病、酒精滥用、癫痫及接受临终关怀者。
临床怎么用
- 对住院后新启用BZD的老年患者,尤其失眠或中重度衰弱者,应关注停药困难并考虑针对性减药策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prolonged benzodiazepine (BZD) use following hospital discharge may heighten the risk of BZD dependence and serious adverse drug events in older adults. However, there is limited understanding of BZD discontinuation pattern and associated factors in this population. METHODS: This retrospective cohort study was conducted using Optum CDM from January 2004 to February 2025. We included patients aged ≥ 65 years who newly initiated a BZD prescription within 30 days of hospitalization. We excluded patients with anxiety, mental illnesses, alcohol abuse, seizure disorder, and those receiving hospice care. BZD discontinuation was defined as a gap exceeding 15 days following the end of a BZD prescription. Discontinuation rates were estimated by the Kaplan-Meier method, and the association between patient characteristics and BZD discontinuation was analyzed using Cox proportional hazards models in the primary analysis. Inverse probability of censoring weight was applied to adjust for the competing risk of death. RESULTS: A total of 33,449 patients were included (mean age [SD]: 73.1 [5.8] years; 51.7% men). The IPW-weighted BZD discontinuation rate by 30, 60, and 90 days was 53.3% (95% CI: 52.7%-53.8%), 86.7% (86.3%-87.1%), and 92.6% (92.3%-93.0%), respectively. The 30-day discontinuation rate increased from 31.7% (29.5%-33.9%) in 2004 to 71.1% (68.7%-73.5%) in 2024. During the study period, an annual 4% increase in the discontinuation rate was observed. Risk factors associated with lower BZD discontinuation were insomnia (hazard ratio [HR]: 0.66 [0.63-0.69]), moderate-to-severe frailty (HR: 0.82 [0.75-0.90]), and new uses of antidepressants (HR: 0.80 [0.76-0.85]) and atypical antipsychotics (HR: 0.90 [0.82-0.99]) following hospitalization and before the first BZD prescription. CONCLUSIONS: Discontinuation rates of BZDs following hospitalization in older adults without a psychiatry history have increased over time. However, challenges remain in discontinuing BZDs, particularly among individuals with insomnia and moderate-to-severe frailty, which may be target populations for developing effective deprescribing strategies in the future.
引用
- Yang CT, Wilkins JM, Pritchard KT, et al. Pattern and Associated Factors of Benzodiazepine Discontinuation Among Older Adults Following Hospitalization. J Am Geriatr Soc. 2025. PMID: 40717214. doi:10.1111/jgs.70018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。